What is GHK-Cu (copper peptide)? Research and status in the Philippines

What is GHK-Cu?

GHK-Cu is copper bound to a small peptide called GHK. GHK is a tripeptide, a chain of three amino acids: glycine, histidine and lysine. Its full name is glycyl-L-histidyl-L-lysine copper complex, and it is also called copper tripeptide or copper peptide GHK-Cu.

Its story starts with lab research on blood:

• 1973: Loren Pickart and Melvin Thaler reported a "tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver". These were lab studies on cells.
• 1977: a follow-up paper by Schlesinger, Pickart and Thaler identified this "growth-modulating serum tripeptide" as glycyl-histidyl-lysine.

Today GHK-Cu is used as an ingredient in topical cosmetic products, such as serums and creams. FDA Philippines has also warned against one unregistered injectable GHK-Cu product (Advisory No. 2026-1278).

How is GHK-Cu thought to work?

Most ideas about how GHK-Cu works come from lab and animal studies, not from studies in people.

• Copper carrier: GHK readily binds copper. In lab studies it increased copper uptake into cultured liver cancer cells, and its discoverers suggested it "may act as a copper transport factor."
• Collagen: in fibroblast cultures (the cells that make connective tissue), GHK-Cu stimulated collagen production. Because the GHK sequence occurs in type I collagen, the authors proposed that it "might be liberated by proteases at the site of a wound and exert in situ healing effects."
• Age: a 2015 review by Pickart and colleagues says GHK is found in human plasma, saliva and urine "but declines with age", and proposes that it works as a complex with copper to speed wound healing and skin repair. The review authors were affiliated with a skin care company.
• Other proposed pathways: a 2026 systematic review lists copper's role in enzymes that cross-link collagen (lysyl oxidases), effects on glycosaminoglycans and TGF-beta3, and antioxidant effects. These come mainly from lab and animal work.

Getting GHK-Cu into the skin is itself a challenge. A 2024 review of topical GHK names skin permeability and the peptide's "hydrophilic" and "unstable nature" as problems for formulation.

Skincare vs injections: what is the difference?

The same ingredient can be regulated differently depending on what a product is meant to do. This section reports regulatory and evidence facts only. It is not a recommendation for either form.

The US FDA defines cosmetics as products intended for "cleansing, beautifying, promoting attractiveness, or altering the appearance". Drugs are products intended to diagnose, cure, mitigate, treat or prevent disease, or "to affect the structure or any function of the body". A product's classification depends on its intended use, including the claims made for it.

A cosmetic notification is a record in the FDA Philippines portal. It should not be read as approval of any health claim made for a product.

What does the human research show?

Human evidence is small and mixed. A 2026 systematic evidence-mapping review found that lab and animal data "consistently support effects on matrix remodeling, epithelial repair, inflammatory/redox regulation, and angiogenesis, but the clinical evidence remains sparse". It concludes that GHK-Cu "should be regarded as a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug."

No human trial of injected GHK-Cu was found.

Points to keep in mind:

• Null results matter: two of the six studies found no difference from placebo or from a regimen without GHK-Cu on objective measures.
• Mixed ingredients: two of the hair and scalp studies did not test GHK-Cu alone.
• Older cosmetic reports: a 2026 review describes older cosmetic reports on GHK-Cu as "small or incompletely characterized".
• Anti-wrinkle use: a 2024 review says that although GHK-Cu is widely used in anti-wrinkle products, "there is a surprising absence of clinical studies using them".

One new trial is underway. NCT07437586 is a phase 2, randomized, quadruple-masked trial in China testing a topical GHK-Cu gel against an inactive gel on small skin wounds in an estimated 60 healthy adults. It is industry sponsored, started recruiting on February 2, 2026, and has an estimated primary completion date of February 14, 2027. No results were posted as of October 7, 2026.

What do animal and lab studies show?

Animal studies of GHK-Cu on wounds have mostly reported positive effects, but not all of them.

Lab studies on cells add the copper transport and collagen findings described above. Results in rats and cell cultures do not show that the same effects happen in people.

Who did the research?

A large share of GHK-Cu research comes from one source. A 2026 systematic review of 64 records found that about 35% of the primary research in its search window includes GHK's co-discoverer, Loren Pickart, or a co-author from his skin care company.

The reviewers note that Pickart "held commercial interests in the field for decades", and that this concentration "limits the independence of the evidence base." They also say that "the clinical literature in humans remains thin and fragmented: most randomized trials are small, conducted on facial cosmetic creams".

Other examples of industry links in the sources:

• The 2015 review proposing how GHK works was written by authors affiliated with a skin care company.
• In the 2024 scalp study, two authors worked for the research organization that ran the study and one for the maker of the test products.
• The phase 2 wound trial now recruiting is industry sponsored.

Risks and unknowns

The safety of GHK-Cu in people is not well characterized, and for injected GHK-Cu no human studies were found.

• Immune reactions with injections: the US FDA says "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations."
• Unregistered products: FDA Philippines says the unregistered injectable GHK-Cu product it warned about gives the public "no assurance as to its quality, safety and efficacy", and that using it "may expose them to potential health risks, including possible injury or harm."
• Skin allergy: a 2026 review notes that "Copper is a recognized contact sensitizer in susceptible individuals". Products that boost penetration, or use on broken skin, increase exposure. The authors say allergy screening is warranted for wound, implant and injectable products.
• Copper build-up: the same review names cumulative copper burden as "the dominant long-term concern". Long-term or large-area skin use, repeated injection or long-dwell implants should be checked for copper build-up in the liver and, at high exposures, the nervous system. It adds that "No validated GHK-Cu-specific human NOAEL, dermal exposure limit, or labile copper safety threshold exists."
• Blood vessel growth: the reviewers note that GHK-Cu's effects on new blood vessel growth may be "undesirable in tumors, proliferative retinopathies, or vascular malformations", and that any injectable or whole-body use should assess this. This is a theoretical concern, not an observed harm.
• What is in the product: a 2026 review notes that "GHK-Cu" is often treated as one defined ingredient "even when the administered material, metal-to-ligand ratio, counterions, pH, competing chelators, purity, and free copper content are not fully reported". Most published studies of GHK-Cu delivery systems do not report a validated sterilization method.

What is still unknown:

• No human study of how the body absorbs, distributes and clears GHK-Cu was found.
• No regulator or peer-reviewed lab analysis of the identity or purity of GHK-Cu products was found.

What is the US FDA's position on GHK-Cu?

The US FDA treats GHK-Cu differently depending on the route. Non-injectable GHK-Cu is under evaluation for use in pharmacy compounding, while injectable GHK-Cu is not.

How the non-injectable listing changed in 2026:

The dates when injectable GHK-Cu was placed in category 2 and when its nomination was withdrawn are not shown on the current FDA pages.

What do anti-doping rules say about GHK-Cu?

GHK-Cu is not named on the World Anti-Doping Agency (WADA) Prohibited List for 2026 or 2027, and no WADA or USADA statement on GHK-Cu itself was found. This page does not say whether it is prohibited or permitted.

What the anti-doping bodies do say:

• WADA class S0: the 2026 list's class S0, non-approved substances, covers "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use". It is prohibited at all times. The 2027 list, in force from January 1, 2027, adds "peptides" to the S0 examples.
• WADA's 2027 explanatory note: "Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health."
• USADA (June 2026): lists Tripeptide-1 (GHK, non-palmitoylated) among example cosmetic peptide ingredients that are "NOT PROHIBITED". USADA also says the WADA list has no route-dependent status for peptides, so "topical use of a growth factor or peptide is just as prohibited as injectable or oral forms" when the peptide itself is prohibited. It does not mention GHK-Cu or injectable use specifically, and advises athletes to check Global DRO.

Status in the Philippines

GHK-Cu's FDA Philippines status depends on the product. No FDA Philippines drug registration for GHK-Cu was found, some topical products containing it appear as notified cosmetics, and FDA Philippines has warned against one unregistered injectable. No compound-level FDA Philippines statement on GHK-Cu was found.

What the FDA Philippines verification portal showed on October 7, 2026 (search results, not an official ruling):

Other points:

• Injectable product warning: in Advisory No. 2026-1278, FDA Philippines found that an injectable GHK-Cu product had no Certificate of Product Registration and warned the public not to purchase or use it.
• Prescription status: no Philippine source (FDA Philippines, DOH, PhilHealth or PRC) on prescription status, compounding or enforcement for GHK-Cu beyond the advisory was found.
• Check a product yourself: FDA Philippines advises the public to check whether products are registered using its verification portal at verification.fda.gov.ph.

For how Philippine rules treat peptides in general, see are peptides legal in the Philippines.

FDA advisory history

FDA Philippines has issued one advisory naming GHK-Cu, and one earlier advisory on a copper peptide product that does not say it contains GHK-Cu.

Both advisories have Filipino versions (No. 2026-1278-A and No. 2020-970-A). On October 7, 2026, searches of the FDA Philippines website for GHK-Cu, GHK, copper peptide, copper tripeptide, tripeptide, copper and peptide found no other relevant advisories.

A missing advisory does not mean a product is registered or approved. For another peptide with little human evidence, see BPC-157.

What to ask a doctor

If you are thinking about GHK-Cu, or already use it, a licensed doctor can help. Questions you could bring:

• What approved treatments exist for my skin, hair or wound concern, and what does the evidence show for them?
• Could a copper-containing skin product cause an allergic reaction for me, given my skin history?
• What should I watch for if I have already injected an unregistered peptide product?
• If I compete in sport, how should I check whether a product is allowed?
• How can I check whether a product is registered or notified with FDA Philippines?